Welcome to our dedicated page for Urovant Sciences news (Ticker: UROV), a resource for investors and traders seeking the latest updates and insights on Urovant Sciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Urovant Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Urovant Sciences's position in the market.
Urovant Sciences (Nasdaq: UROV) announced that CEO James Robinson will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 6:10 p.m. GMT. A live audio webcast will be accessible on the company's Investor Relations website and will remain available for replay for approximately seven days. Urovant is focused on developing therapies for urologic conditions with its lead candidate, vibegron, showing positive results for overactive bladder. The company aims to innovate further in urologic disease treatments.
Urovant Sciences (Nasdaq: UROV) reported its financial results for Q2 fiscal 2020, ending September 30, highlighting key operational milestones ahead of the FDA's decision on vibegron for overactive bladder (OAB) by December 26, 2020. A significant co-promotion agreement with Sunovion Pharmaceuticals was established to enhance commercial reach targeting primary care physicians. The total operating expenses were $33.5 million, with a net loss of $35.2 million, or $1.12 per share. The company had cash reserves of $74.4 million as of the reporting date.
Urovant Sciences (Nasdaq: UROV) has announced a five-year co-promotion agreement with Sunovion Pharmaceuticals to market vibegron in the U.S. after receiving FDA approval. This partnership allows Urovant to expand its reach into primary care without upfront costs until March 2026. Sunovion's multi-specialty sales force will target primary care physicians, while Urovant will focus on urologists. The agreement complements a previous three-year deal for distribution and marketing services, enhancing Urovant's market presence for vibegron, which is aimed at treating overactive bladder.
